secwatch.observer — SEC 8-K summary
======================================

Issuer:     PETMED EXPRESS INC (PETS)
CIK:        0001040130
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001040130-24-000004
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PetMeds restates FY2021-2023 financials, preliminary Q3 sales up 11% YoY to $65.3M
--------------------------------------------------------------------------------

- Restatement covers FY2021-2023 and Q1/Q2 FY2024 due to sales tax and deferred tax errors.
- Preliminary Q3 net sales $65.3M (+11% YoY); gross margin 27.4% vs 25.9% prior year.
- Sales tax liability expected $14-20M as of Mar.2020, $16-23M as of Mar.2023; FY2023 G&A decrease $6-8M.
- Deferred tax asset from PetCareRx acquisition to be restated: increase goodwill, decrease deferred tax asset.
- Q3 10-Q filing delayed; no impact on FY2024 revenue, COGS, or cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1040130/000104013024000004/0001040130-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1040130/000104013024000004/pets-20240207.htm
  HTML page:      https://secwatch.observer/filing/0001040130-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer